Stretching accelerated approval

FDA wants to stretch its accelerated approval pathway beyond traditional surrogate endpoints to include overall survival that has been demonstrated in small trials, such as exploratory studies.

The change is a response to advances in targeted drug development that are making it increasingly possible to identify potential breakthroughs early in clinical development. ...